Recently, following the pioneering application of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of uterine fibroids in China, the first case of MRgFUS for metastatic bone tumors in China was successfully performed in our hospital. The first patient was a 32-year-old patient with iliac bone metastasis from adenoid soft tissue sarcoma, a pathological type of tumor that is insensitive to radiotherapy and chemotherapy. On July 16, 2014, we performed a non-invasive treatment procedure on this patient. The surgery started at 17:30 pm and lasted for about 1.5 hours and was completed in the MRgFUS operating room of the Department of Radiology . During the operation, the metastatic bone tumor was ablated by controlled excitation of focused ultrasound pulses, and the temperature of the target site reached 65-100 degrees Celsius with real-time temperature monitoring, which completely “burned” the local tumor cells. The patient had no obvious discomfort during the whole procedure, and the safety and effectiveness of the procedure were ensured by real-time cardiac monitoring, magnetic resonance imaging and in vivo multi-point temperature measurement. On July 17, the team successfully performed non-invasive treatment on another patient with bone metastases from lung cancer. Bone is one of the three most common sites of cancer metastasis, and more than 50% of cancer patients will develop bone metastasis, especially in patients with lung, breast, and prostate cancers. According to statistics, the incidence of bone metastases is 35-40 times higher than that of primary malignant tumors of bone, which shows how harmful it is. And cancer bone metastasis is also one of the most important causes of cancer pain, which often seriously affects the survival quality of cancer patients, accelerates the development of the disease, and even causes pathological fracture. Although the medical profession has not yet found an effective method to cure metastatic bone tumors, with the updating of medical concept and social medical model, it should be recognized that the occurrence of bone metastasis is not always the terminal stage of cancer patients, and proper treatment has definite efficacy in reducing pain, improving the quality of survival, and even in prolonging the survival period. Patients with metastatic bone tumors often have their quality of life seriously affected by severe pain. After being the first in China to apply magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of uterine fibroids, the Department of Radiology of our hospital has recently been the first in China to apply this high-tech non-invasive treatment technology for the treatment of metastatic bone tumors, and has achieved initial good results. This technology was approved by the U.S. Food and Drug Administration (FDA) at the end of 2012, and our hospital is now the first to undertake the domestic clinical study of this technology, which is mainly for the treatment of metastatic bone tumors, especially for patients with metastatic bone tumors that have failed radiotherapy or chemotherapy. The corresponding clinical results will be used for the approval and certification of the technology by the China Food and Drug Administration (CFDA). For the smooth development and advancement of this new technology, Shanghai First People’s Hospital has established a multidisciplinary expert team consisting of radiology, orthopedics, oncology and anesthesiology, led by Professor Guixiang Zhang from radiology and Professor Zhengdong Cai from orthopedics.